DIAGNOS declares inventory possibility grants

BROSSARD, Quebec, March 3, 2021 (GLOBE NEWSWIRE) – Diagnos Inc. (“DIAGNOS” or “the Firm”) (TSX Enterprise: ADK) (OTCQB: DGNOF), a pacesetter within the early detection of important well being issues because of using his FLAIRE platform primarily based on synthetic intelligence (AI), declares grants totaling 125,000 inventory choices to 2 of its executives. Inventory choices vest at 50% per yr, beginning on the primary anniversary of the grant. The train value of those inventory choices has been established at $ 0.57 per share. The expiration date on which these inventory choices will be exercised has been set for March 2, 2026.

All sums cited on this press launch shall be declared and paid within the authorized tender of Canada.

About DIAGNOS
DIAGNOS is a Canadian publicly traded firm devoted to the early detection of important well being issues via its synthetic intelligence FLAIRE (AI) Platform. FLAIRE permits speedy modification and improvement of functions equivalent to CARA (Pc Assisted Retina Evaluation). CARA’s AI-based picture enhancement algorithms ship sharper, clearer, and simpler to investigate retinal pictures. CARA is a cheap software for real-time screening of enormous volumes of sufferers. CARA has been accredited for advertising and marketing by the next regulatory companies: Well being Canada, FDA (United States), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Extra info is offered at www.diagnos.com and www.sedar.com.

This press launch accommodates forward-looking info. There will be no assurance that forward-looking info will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in such statements. DIAGNOS disclaims any intention or obligation to publicly replace or revise any forward-looking info, whether or not on account of new info, future occasions or in any other case. The forward-looking info contained on this press launch is expressly certified by this cautionary assertion.

Neither the TSX Enterprise Change nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Change) accepts accountability for the adequacy or accuracy of this launch.

CONTACT: For additional info, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 [email protected]

Supply hyperlink

About Eric Harris

Eric Harris

Check Also

Translate Organic Reporting Incentive Grants Underneath Nasdaq Itemizing Rule 5635 (c) (4)

LEXINGTON, Mass., March 3, 2021 (GLOBE NEWSWIRE) – Translate Bio (TBIO), a clinical-stage messenger RNA …